
APO · NYSE
Consensus is Buy across 14 analysts, with a reported mean price target of $148. The summary provides no low or high target, so where targets cluster and how wide the spread is cannot be assessed; it also names no analyst or firm as most or least bullish. No rating or target revisions are supplied for the week, so revision direction is unavailable. The substantive disagreement evident in the research is earnings quality: revenue beat estimates by 2.31% and higher AUM supported the outlook, while adjusted net income missed by 3.21% as expenses increased. FY2025 revenue also rose, but net income declined versus FY2024.